Pharmaceutical industry – Page 31
-
BusinessBiogen pays $1.25bn to protect multiple sclerosis drug sales
Agreement with Forward Pharma gives Biogen license to keep selling blockbuster Tecfidera
-
OpinionDrug regulation is a burden worth bearing
Calls to break down regulatory barriers show a misunderstanding of the industry
-
Business
Novartis on winter deal spree
Swiss company aims to re-stock drug pipeline with three new deals in skin, eye and cardiovascular health
-
ResearchDrug binding simulations promise to get personal
Fast, reliable new molecular dynamic simulation methods set to speed up research are under investigation by GSK
-
BusinessCholesterol drug withdrawn in patent dispute
Ruling that Regeneron’s Praluent antibody infringes Amgen’s Repatha patent could stifle innovation
-
BusinessIpsen to buy Merrimack’s cancer drugs
$1bn deal covers two liposome-encapsulated formulations of approved therapies
-
BusinessTaming vaccines with chemistry
Vaxxilon aims to simplify vaccine development by replacing biological components with well-defined synthetic molecules
-
BusinessTakeda to buy cancer specialist Ariad
Japan’s largest drug company agrees $5.2bn deal to expand oncology portfolio and boost pipeline
-
BusinessIndian court revokes ban on combination drugs
Companies claim government failed to follow procedure in restricting risky medicines
-
BusinessTeva fined $520m for corruption
World’s largest generics manufacturer admits paying bribes in Russia, Ukraine and Mexico
-
-
-
BusinessMylan may lay off up to 3500 staff
The move forms part of the US generic firm’s restructuring efforts
-
BusinessLonza to buy capsule manufacturer in $5.5bn deal
Swiss pharma firm looks to strengthen its position as world’s biggest drug manufacturing subcontractor
-
BusinessUS pharma executives face bribery charges over opioid painkiller prescriptions
Insys Therapeutics chief executive and senior managers accused of running a conspiracy to bribe doctors across several states
-
BusinessBristol-Myers Squibb planning huge reorganisation in the US
Job losses likely as Hopewell, New Jersey site will close by 2020
-
CareersCatching up with AstraZeneca's graduate programme
Three years on, Manisha Lalloo revisits the pharma giant’s training scheme
-
BusinessPharmaceutical industry roundup of 2016
Controversial approvals and price clashes characterised 2016 in pharma
-
BusinessEndo drops opioid painkiller rights and cuts US sales force
375 staff to go as Endo says its established pain drugs ‘no longer require field promotion’
-
BusinessBoehringer Ingelheim sheds more jobs in the US
Over 240 staff to go as company refocuses on immuno-oncology